Skip to main content
Clinical Trials/NCT04229485
NCT04229485
Unknown
Not Applicable

The Chinese Cohort Study of Chronic Kidney Disease Patients Followed on Smartphone Platform, a Multi-center Observational Study

Limeng Chen1 site in 1 country3,360 target enrollmentJanuary 10, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Kidney Diseases
Sponsor
Limeng Chen
Enrollment
3360
Locations
1
Primary Endpoint
incidence of progression to ESRD
Last Updated
6 years ago

Overview

Brief Summary

This is a multi-center prospective cohort study. The purpose of this study is to investigate the relationship between bone metabolic markers and other non-traditional risk factors with kidney function progression, cardiovascular and cerebrovascular diseases, and bone loss in patients with CKD G3-5ND. In the meantime, this study is to explore a new mode of management and complication monitoring through mobile communication in chronic kidney disease patients.

Detailed Description

Abnormal mineral bone metabolism of chronic kidney disease (CKD-MBD) is the most common complication of CKD. It involves kidney, bone metabolism, parathyroid gland, cardiovascular and cerebrovascular organs. It is an independent risk factor for progression of CKD to end-stage renal disease (ESRD), vascular and cardiac valve calcification, and cardiovascular and cerebrovascular events. However, less data concerning the relationship between bone metabolic index, such as high blood phosphorus and cardiovascular diseases, bone mass reduction and fracture is available in Chinese adult patients. This study is a multi-center prospective cohort study to explore the relationship between bone metabolic markers and other non-traditional risk factors with renal function progression, cardiovascular and cerebrovascular diseases, and bone loss in patients with CKD G3-5ND. Based on the sample size estimation, 3360 subjects should be enrolled in this study. The primary outcome is progression to ESRD (start dialysis or kidney transplantation) or doubling of serum creatinine, as well as cardiovascular events and all-cause mortality. At present, the follow-up and the management of complications of CKD patients are not enough. The popularity of mobile communication in China provide the possibility to strengthen the follow-up and complications management in CKD patients and save human resources. This study is to explore a new mode of collecting datas through mobile communication in chronic kidney disease patients.

Registry
clinicaltrials.gov
Start Date
January 10, 2020
End Date
December 31, 2023
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Limeng Chen
Responsible Party
Sponsor Investigator
Principal Investigator

Limeng Chen

Professor of Medicine, Associate Chief of Nephrology Division

Peking Union Medical College Hospital

Eligibility Criteria

Inclusion Criteria

  • at least two measurements of serum Cr (with a minimum interval of 3 months), , 10≤eGFR≤60ml/min/1.73m\^2

Exclusion Criteria

  • Unable or unwilling to provide informed consent
  • Patients attending oncology, psychiatry, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), viral hepatitis (HBV or HCV) services
  • Acute mycardial infarction within the last six months
  • NYHA Class III or IV heart failure at baseline
  • Ongoing chemotherapy or immunosuppressive therapy (in the preceding 6 months to treat renal or immune disease)
  • Current renal replacement therapy
  • Current pregnancy or breastfeeding women
  • Any organ transplantation
  • Currently participation in an interventional clinical trial

Outcomes

Primary Outcomes

incidence of progression to ESRD

Time Frame: 2 year

begin to dialysis and kidney transplantation

cardiovascular event and all-cause mortality

Time Frame: 2 year

diagnose as myocardial infarction, heart failure, stroke and cerebral hemorrhage

Secondary Outcomes

  • the rate of eGFR decline(2 years)
  • bone mass change(2 years)
  • Kidney Disease Outcomes Quality Initiative-Short Form 36(2 years)
  • frailty(2 years)
  • the way of dialysis initiation(2 years)

Study Sites (1)

Loading locations...

Similar Trials